Lataa...
In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium
Mycoplasma genitalium has developed resistance to first-line azithromycin and second-line moxifloxacin. Third-line pristinamycin is only 75% effective. Gepotidacin, a novel triazaacenaphthylene topoisomerase II inhibitor, blocks bacterial DNA replication. We determined the in vitro activity of gepot...
Tallennettuna:
| Julkaisussa: | Emerg Microbes Infect |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7473033/ https://ncbi.nlm.nih.gov/pubmed/32552547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/22221751.2020.1775498 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|